Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 57
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Gynecol Oncol ; 88(3): 429-33, 2003 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12648598

RESUMEN

OBJECTIVE: In vitro studies have revealed that treatment of various human cancer cell lines with specific cyclo-oxygenase 2 (COX-2) inhibitors induces apoptotic cell death. It is currently proposed that the combination of COX-2 inhibitors with chemotherapeutic agents improves the efficacy of cancer treatment. MATERIALS AND METHODS: In this study we sought to determine the effects of combining paclitaxel and the COX-2 inhibitor NS398 on apoptosis of epithelial ovarian cancer (EOC) cells. Two EOC cell lines, SKOV3 and MDAH2774, were exposed to increasing concentrations of paclitaxel (0.1, 10, and 100 microM) and NS398 (10, 100 microM) as well as a combination of both drugs. Apoptosis was evaluated by the Tunel assay. The fluorescein-labeled DNA was visualized directly by fluorescence microscopy and quantitated by flow cytometry. RESULTS: While NS398 did not significantly alter apoptosis of either EOC cell lines after 24 h of continuous exposure, treatment of both cell lines with paclitaxel resulted in a significant increase in the rate of apoptosis (60-70%). Concomitant treatment of both SKOV3 and MDAH2774 cells with paclitaxel and NS398 resulted in marked impairment of paclitaxel-induced apoptosis. Similarly, sequential treatment during which both cell lines were treated with NS398 for 4 h, triple-washed, and then exposed to paclitaxel for 24 h resulted in a significant inhibition of paclitaxel-induced apoptosis. Similar inhibition was seen when NS398 was replaced by aspirin. CONCLUSIONS: Combining COX-2 inhibitors and paclitaxel does not have an additive or synergistic tumoricidal effect. On the contrary, NS398 treatment markedly inhibited the apoptotic effects of paclitaxel in each of these two EOC cell lines.


Asunto(s)
Antineoplásicos Fitogénicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Apoptosis/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Isoenzimas/antagonistas & inhibidores , Nitrobencenos/farmacología , Neoplasias Ováricas/tratamiento farmacológico , Paclitaxel/antagonistas & inhibidores , Sulfonamidas/farmacología , Antineoplásicos Fitogénicos/administración & dosificación , Aspirina/administración & dosificación , Aspirina/farmacología , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/administración & dosificación , Interacciones Farmacológicas , Femenino , Citometría de Flujo , Humanos , Proteínas de la Membrana , Nitrobencenos/administración & dosificación , Neoplasias Ováricas/patología , Paclitaxel/administración & dosificación , Paclitaxel/farmacología , Prostaglandina-Endoperóxido Sintasas , Sulfonamidas/administración & dosificación , Células Tumorales Cultivadas
3.
J Soc Gynecol Investig ; 7(3): 184-9, 2000.
Artículo en Inglés | MEDLINE | ID: mdl-10865187

RESUMEN

OBJECTIVES: To determine whether a Bcl-x(S) adenoviral vector has therapeutic potential in an ascites model of human breast cancer in nude mice. METHODS: Advanced ascites were developed by injecting mice intraperitoneally (IP) with MDA-MB-231 human breast carcinoma cells. Mice received sequential IP injections of the Bcl-x(S) virus or a control lac-Z adenovirus. A third group of mice received no virus. Tumor burden and survival were monitored. Histopathology and necropsies were performed on mice. RESULTS: A single injection of the Bcl-x(S) adenovirus produced no systemic or local toxicity and no abnormal histopathology in normal mice. However, abdominal organs within these mice were transduced with the Bcl-x(S) vector. Adenoviral gene transduction efficiency in MDA-MB-231 ascites was 36+/-6.40% (n = 3). Percent weight change differences revealed that ascites bearing mice injected three times with the Bcl-x(S) vector showed a statistically significant decrease in tumor burden compared with lac-Z-injected mice (n = 7; P = .012 on days 10-15 after the first injection). Mice injected with the Bcl-x(S) vector had significantly greater survival relative to lac-Z-injected mice (n = 7; P = .0004). Bcl-x(S) protein expression was detected in aspirates of mice injected with the Bcl-x(S) vector but not the lac-Z vector. Necropsies revealed that ascites bearing mice injected with Bcl-x(S) vector lacked carcinoma in the peritoneal cavity compared with control mice. CONCLUSION: The Bcl-x(S) adenovirus can reduce tumor burden and increase survival in an ascites model of advanced stage breast cancer.


Asunto(s)
Adenoviridae , Ascitis/terapia , Neoplasias de la Mama/terapia , Modelos Animales de Enfermedad , Terapia Genética , Proteínas Proto-Oncogénicas c-bcl-2/genética , Animales , Apoptosis , Neoplasias de la Mama/patología , Supervivencia Celular , Femenino , Expresión Génica , Vectores Genéticos , Humanos , Ratones , Ratones Desnudos , Trasplante de Neoplasias , Peritoneo/patología , Proteínas Proto-Oncogénicas c-bcl-2/fisiología , Células Tumorales Cultivadas , Proteína bcl-X
4.
Zhonghua Fu Chan Ke Za Zhi ; 35(2): 94-7, 2000 Feb.
Artículo en Chino | MEDLINE | ID: mdl-11809108

RESUMEN

OBJECTIVE: To observe the presence of synergistic efficacy between adenovirus-mediated bcl-Xs (Adv-bcl-Xs) gene therapy and cisplatin (CDDP) in ovarian cancer cell. METHODS: NuTu-19 cells were infected by different titers of Adv-bcl-Xs and treated with CDDP in the meantime. Percentage of cell proliferation was measured by methyl thiazolyl tetrazolium and cell cycles were measured by flow cytometry 3 days later. Graphical representations of the statistical analyses for their interaction in tumor cells. RESULTS: The statistical results and Graphical representations of the statistical modeling showed that the synergistic antiproliferative activity was present (P < 0.01). CONCLUSION: There was synergistic efficacy between Adv-bcl-Xs gene and CDDP for the inhibition of ovarian cancer cell.


Asunto(s)
Adenovirus Humanos/genética , Antineoplásicos/farmacología , Cisplatino/farmacología , Terapia Genética , Neoplasias Ováricas/patología , Proteínas Proto-Oncogénicas c-bcl-2/genética , Animales , División Celular/efectos de los fármacos , Femenino , Terapia Genética/métodos , Ratas , Transfección , Células Tumorales Cultivadas , Proteína bcl-X
5.
J Soc Gynecol Investig ; 5(5): 277-80, 1998.
Artículo en Inglés | MEDLINE | ID: mdl-9773404

RESUMEN

OBJECTIVE: Hox genes encode DNA transcription regulatory proteins that contain a conserved 61 amino acid protein called the homeodomain. Although best known for their role in cellular differentiation during embryonic development, aberrant expression of these genes has been associated with hematologic and solid neoplasms. The purpose of this study was to determine the relative expression of HOXD10 in human endometrial adenocarcinomas. METHODS: mRNA was isolated from 7 normal endometrial specimens and 28 endometrial adenocarcinoma specimens. cDNA was synthesized using random hexamer primers. The expression of HOXD10 relative to beta-tubulin (internal control) was assessed by densitometric comparison of co-amplified Phosphorus-32 (32P) labeled gene products separated by agarose gel electrophoresis. Direct sequencing of purified HOXD10 polymerase chain reaction product was also performed. RESULTS: The sequence of the purified HOXD10 product corresponds to the known DNA sequence reported in the National Institute of Health Gene Bank. mRNA expression of HOXD10 relative to beta-tubulin is significantly lower in endometrial carcinomas than in normal endometrium. Furthermore, the ratio of HOXD10 to beta-tubulin expression varies inversely with the histologic grade of the tumor (P = .0009). CONCLUSION: Cancer is a multistep process involving the aberrant expression of genes that regulate cell growth and differentiation. Human HOXD10 gene expression is altered in endometrial carcinoma and varies with the histologic grade of differentiation. This observation supports the theory that homeobox genes play a role in oncogenesis.


Asunto(s)
Adenocarcinoma/metabolismo , Neoplasias Endometriales/metabolismo , Endometrio/metabolismo , Expresión Génica , Proteínas de Homeodominio/genética , Factores de Transcripción/genética , Proteínas de Pez Cebra , Femenino , Humanos , Reacción en Cadena de la Polimerasa , ARN Mensajero/metabolismo , Análisis de Secuencia de ADN , Tubulina (Proteína)/genética
6.
Gynecol Oncol ; 70(2): 202-9, 1998 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-9740691

RESUMEN

OBJECTIVES: Endometrial carcinoma cell lines were evaluated for epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), and insulin-like growth factor I (IGF-1) production and for autocrine stimulation. METHODS: Conditioned, serum-free media (CM) from cell lines RL95-2, KLE, HEC, and Ishikawa (ISH) were concentrated radioimmunoassayed (RIA). Samples for the IGF-1 assay were extracted with acid-ethanol to remove IGF-1 binding protein. Polymerase chain reaction (PCR) was used to validate the presence of mRNA for growth factors and receptors. Cells were incubated with Ab528, an antibody blocking EGF receptors, and alphaIR3, an antibody blocking IGF-1 receptors. Proliferation was quantified using [3H]thymidine incorporation. RESULTS: TGF-alpha was detected in CM: RL95-2 (0.4 +/- 0.001 ng/ml), KLE (0.7 +/- 0.003 ng/ml), HEC (0.8 +/- 0.01 ng/ml), ISH (1.2 +/- 0.05 ng/ml). No EGF was detected in CM. In extracted samples, IGF-1 was detected in CM: RL95-2 (0.8 +/- 0. 03 ng/ml), KLE (1.25 +/- 0.02 ng/ml), HEC (1.6 +/- 0.01 ng/ml), ISH (1.6 +/- 0.08 ng/ml). Unconditioned media served as the control. EGF, TGF-alpha, and IGF-1 mRNA was identified in all cell lines, as was the mRNA for EGF and IGF-1 receptors. Incubation with Ab528 or alphaIR3 resulted in significant inhibition of DNA synthesis in HEC 1A, KLE, and ISH. No inhibition was detected in the RL95-2 cell line. A control antibody did not inhibit the cell lines. CONCLUSION: Autocrine production and stimulation of endometrial carcinoma cell lines by TGF-alpha and IGF-1 are demonstrated in three of four endometrial cancer cell lines. No measurable EGF was produced by any of the cell lines.


Asunto(s)
Comunicación Autocrina/fisiología , Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Factor de Crecimiento Epidérmico/metabolismo , Factor I del Crecimiento Similar a la Insulina/metabolismo , Proteínas de Neoplasias/metabolismo , Factor de Crecimiento Transformador alfa/metabolismo , División Celular , Medios de Cultivo Condicionados , Medio de Cultivo Libre de Suero , ADN de Neoplasias/metabolismo , Femenino , Humanos , Reacción en Cadena de la Polimerasa , ARN Mensajero , Células Tumorales Cultivadas
7.
Am J Obstet Gynecol ; 177(1): 120-5, 1997 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9240594

RESUMEN

OBJECTIVES: Our purpose was to determine the molecular profile of advanced-stage transitional cell carcinoma in terms of immunostaining for p53, epidermal growth factor receptor and HER-2/neu, deoxyribonucleic acid index, and S-phase fraction and to analyze the prognostic significance of these markers. STUDY DESIGN: Archival paraffin-embedded tissue blocks from 29 advanced stage transitional cell carcinomas were obtained. Selected sections of the primary tumors were immunostained for p53, epidermal growth factor receptor, and HER-2/neu; deoxyribonucleic acid ploidy and S-phase fraction were determined with use of flow cytometry. Clinical information was abstracted from the medical records. Survival times were analyzed according to the life-table methods of Kaplan and Meier, and the statistical significance of the various factors was tested with the log-rank test. The proportional hazards model of Cox was used to identify prognostic factors. RESULTS: Positive immunostaining was observed for p53 in 13 cases (45%), for epidermal growth factor receptor in 14 cases (50%), and for HER-2/neu in 19 cases (65%). Tumors were diploid in 16 cases (55%) and aneuploid in 13 (45%). The S-phase fraction was < or = 15% (mean) in 13 cases (45%) and > 15% in 16 cases (55%). The median survival for the entire group was 52 months. None of the above variables had a significant effect on survival time. CONCLUSION: Neither immunostaining for p53, epidermal growth factor receptor, and HER-2/neu nor deoxyribonucleic acid ploidy nor S-phase fraction allowed us to distinguish transitional cell carcinoma from other more common epithelial ovarian cancers. In addition, no prognostic significance was associated with these biomarkers. A study of larger numbers of cases may be more elucidative.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma de Células Transicionales/química , ADN de Neoplasias/análisis , Receptores ErbB/análisis , Neoplasias Ováricas/química , Receptor ErbB-2/análisis , Proteína p53 Supresora de Tumor/análisis , Adulto , Anciano , Carcinoma de Células Transicionales/patología , Ciclo Celular/fisiología , Femenino , Citometría de Flujo , Humanos , Inmunohistoquímica , Tablas de Vida , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/patología , Estudios Retrospectivos , Fase S
8.
Gynecol Oncol ; 65(1): 63-8, 1997 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-9103392

RESUMEN

Growth factor regulation of normal and cancerous cell proliferation has been well-documented and may be mediated by proto-oncogene activity. The purpose of this study was to assess changes in proliferation and mitogen-induced c-fos mRNA expression of an endometrial carcinoma cell line, HEC-1-A, in response to TGF-beta, a potent growth-inhibitory peptide. HEC-1-A cells were incubated in the presence or absence of TGF-beta. Mitogen-stimulated cells were additionally treated with epidermal growth factor (EGF). Changes in proliferation were measured by [3H]thymidine uptake assays. Alterations in EGF-induced c-fos expression following TGF-beta pretreatment were assessed by Northern blot using a 32P-labeled human c-fos probe. Finally, chloramphenicol acetyltransferase assays were performed to evaluate c-fos promoter activity in response to treatment conditions. Basal and EGF-stimulated proliferation was inhibited by TGF-beta in a dose- and time-dependent manner. TGF-beta also reversibly decreased EGF-induced c-fos mRNA expression in a dose- and time-dependent manner. Sequences in the c-fos promoter that were stimulated by EGF showed suppressed activity when preincubated with TGF-beta. These results show that TGF-beta negatively modulates EGF-induced c-fos expression, which may be related to the observed inhibition of carcinoma cell proliferation.


Asunto(s)
Adenocarcinoma/química , Adenocarcinoma/patología , Neoplasias Endometriales/química , Neoplasias Endometriales/patología , Proteínas Proto-Oncogénicas c-fos/análisis , Factor de Crecimiento Transformador beta/farmacología , Adenocarcinoma/genética , Northern Blotting , División Celular/efectos de los fármacos , División Celular/fisiología , ADN de Neoplasias/análisis , ADN de Neoplasias/genética , ADN de Neoplasias/metabolismo , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Neoplasias Endometriales/genética , Factor de Crecimiento Epidérmico/farmacología , Femenino , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Genes fos/genética , Humanos , Regiones Promotoras Genéticas/genética , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas c-fos/biosíntesis , Proteínas Proto-Oncogénicas c-fos/genética , ARN Mensajero/análisis , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Factores de Tiempo , Transfección , Tritio , Células Tumorales Cultivadas
9.
J Soc Gynecol Investig ; 4(2): 95-102, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9101469

RESUMEN

OBJECTIVE: The recently cloned gene p16 (MST1) has been identified as a putative tumor suppressor gene that binds to CDK4 and CDK6 (cyclin-dependent kinases), preventing their interaction with cyclin D1 and thereby preventing cell cycle progression at the G1 stage. In addition, the p16 gene has been shown to have a high frequency of mutation in some tumor cell lines; however, it has also been shown that a much lower frequency of mutation occurs in primary tumors. This study investigated the mRNA expression level and mutation status of the p16 gene in ovarian tumors. METHODS: We performed quantitative polymerase chain reaction and direct cDNA sequencing analysis. To confirm the p16 protein level in ovarian tumors, Western blotting and immunohistochemical staining were performed. Expression levels of mRNA for the p16 gene relative to the beta-tubulin gene were examined in 32 ovarian tumors (24 carcinomas, six low malignant potential tumors, and two benign tumors) and six normal ovaries. RESULTS: The mRNA expression level of p16 was significantly elevated in 28 ovarian tumors (22 carcinomas, five low malignant potential tumors, and one benign tumor) compared with that of normal ovaries. Western blotting analysis and immunohistochemical staining confirmed elevated p16 protein levels in ovarian tumor samples. Among 32 ovarian tumors, cDNA sequencing of the p16 gene showed no p16 mutation resulting in a coding error, although one silent mutation and three polymorphisms were found. CONCLUSIONS: Although p16 is seldom mutated in ovarian tumors, the overexpression of p16 in most ovarian tumor cases indicates a dysfunction in the regulatory complex for G1 arrest. Therefore, overexpression of p16 may be an important early event in the neoplastic transformation of the ovarian epithelium.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma/genética , Proteínas Portadoras/análisis , Transformación Celular Neoplásica/genética , Regulación Neoplásica de la Expresión Génica/genética , Mutación/genética , Neoplasias Ováricas/genética , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/inmunología , Western Blotting , Carcinoma/patología , Proteínas Portadoras/genética , Proteínas Portadoras/inmunología , Inhibidor p16 de la Quinasa Dependiente de Ciclina , Cartilla de ADN/química , Epitelio/inmunología , Epitelio/ultraestructura , Femenino , Genes Supresores de Tumor/genética , Marcadores Genéticos/genética , Humanos , Inmunohistoquímica , Neoplasias Ováricas/patología , Ovario/química , Ovario/patología , Reacción en Cadena de la Polimerasa , ARN Mensajero/análisis , ARN Mensajero/genética
11.
Obstet Gynecol Clin North Am ; 23(2): 325-45, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784884

RESUMEN

Vaginal cancer is infrequent, but the morbidity associated with treatment is high. Delays in diagnosis account for presentations in advanced stages. Screening is probably not warranted given the low incidence, but inspection of the vagina should be performed at the time of Pap smear screening. No molecular markers are currently promising. Chemoprevention with retinoids may be feasible.


Asunto(s)
Carcinoma in Situ/patología , Neoplasias Vaginales/patología , Carcinoma in Situ/epidemiología , Carcinoma in Situ/terapia , Femenino , Humanos , Tamizaje Masivo , Factores de Riesgo , Neoplasias Vaginales/epidemiología , Neoplasias Vaginales/terapia
12.
Obstet Gynecol Clin North Am ; 23(2): 295-324, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784883

RESUMEN

Vulvar carcinoma is a rare cancer. It is more frequent among older women, but the incidence is increasing among younger women. The incidence of VIN may be rising in younger women as well. Different factors have been associated with an increased risk for vulvar cancer (HPV, age, smoking, education, diet, genital infections, infrequent pelvic examinations, socioeconomic status, immunosuppressive diseases); however, conclusive epidemiologic evidence is lacking. More studies with larger sample sizes are needed to understand more fully the role of these and other as yet unknown factors in the etiology of vulvar cancer. At present, studies of the molecular risk assessment for VIN and vulvar cancer focus mostly on HPV. The treatments for VIN are painful, and the disease has a high risk of recurrence. The treatments for vulvar cancers are morbid, even though radical vulvectomy is being replaced by the less morbid wide local excision and unilateral groin lymph node dissection. Therefore, VIN and vulvar cancer benefit from early detection, and their morbidity is decreased by early treatment. Screening should be performed by the primary care practitioner and should focus on women with HPV; women who smoke; and women who have other preinvasive disease of the cervix, vagina, or perianal area. Chemoprevention and an HPV vaccine may eventually be promising, but no studies have yet been performed. Patients should be educated about performing vulvar self-examination stopping smoking, being persistent about insisting on a biopsy if symptoms persist, and avoiding exposure to HPV.


Asunto(s)
Carcinoma in Situ/epidemiología , Carcinoma in Situ/patología , Neoplasias de la Vulva/epidemiología , Neoplasias de la Vulva/patología , Biomarcadores de Tumor , Carcinoma in Situ/genética , Carcinoma in Situ/terapia , Femenino , Humanos , Tamizaje Masivo , Estadificación de Neoplasias , Factores de Riesgo , Neoplasias de la Vulva/genética , Neoplasias de la Vulva/terapia
13.
Obstet Gynecol Clin North Am ; 23(2): 347-410, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784885

RESUMEN

Cervical cancer remains an important health problem for women worldwide, despite its decline in countries where organized screening programs are in place. The morbidity of treatment and the mortality for advanced lesions are high, a frustrating situation because the cervix is accessible and a good screening test, the Pap smear, exists. HPV is an important risk factor, and the molecular evidence for its role is overwhelming. Molecular markers may soon help us decide which lesions are at highest risk of progression to invasion and which invasive lesions are likely to recur. Chemoprevention of precursor lesions is promising. An HPV vaccine could be effective in eradicating this cancer.


Asunto(s)
Displasia del Cuello del Útero/patología , Neoplasias del Cuello Uterino/patología , Biomarcadores de Tumor , Femenino , Humanos , Estilo de Vida , Tamizaje Masivo , Factores de Riesgo , Neoplasias del Cuello Uterino/epidemiología , Neoplasias del Cuello Uterino/genética , Neoplasias del Cuello Uterino/terapia , Displasia del Cuello del Útero/epidemiología , Displasia del Cuello del Útero/genética , Displasia del Cuello del Útero/terapia
14.
Obstet Gynecol Clin North Am ; 23(2): 411-56, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784886

RESUMEN

Endometrial cancer is the most frequently seen gynecologic neoplasm, but it fortunately has low mortality, which is due largely to its presentation with abnormal bleeding and its subsequent early diagnosis. The morbidity associated with therapy for early lesions is moderate. Hyperplasia with atypia should be treated as early cancers. Many molecular markers are currently under study. Markers may soon help us identify invasive lesions at higher risk of recurring and thus more suitable for adjunct therapy. Screening in the general population is not recommended, but a high-risk group that is more suitable for screening could be identified, including obese and nulliparous women, those treated with unopposed estrogen or tamoxifen, or those with family or past histories of breast or colon cancer. Development of chemoprevention with an oral contraceptive during the reproductive years is under way, and there may be a role for chemoprevention in the reversal of hyperplasias.


Asunto(s)
Hiperplasia Endometrial/epidemiología , Neoplasias Endometriales/epidemiología , Biomarcadores de Tumor , Hiperplasia Endometrial/genética , Hiperplasia Endometrial/patología , Hiperplasia Endometrial/terapia , Neoplasias Endometriales/genética , Neoplasias Endometriales/mortalidad , Neoplasias Endometriales/patología , Neoplasias Endometriales/terapia , Femenino , Humanos , Tamizaje Masivo , Factores de Riesgo
15.
Obstet Gynecol Clin North Am ; 23(2): 457-73, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784887

RESUMEN

Sarcomas are rare tumors with unpredictable prognosis. They are treated similarly to endometrial cancers. Little is known of epidemiologic risk factors for sarcoma; similarly, little work has been performed assessing molecular alterations in sarcomas. Because of their rarity, uterine sarcomas are not suitable for screening. Chemoprevention studies might target those at risk for recurrence or a second neoplasm.


Asunto(s)
Sarcoma/patología , Neoplasias Uterinas/patología , Biomarcadores de Tumor , Femenino , Humanos , Tamizaje Masivo , Factores de Riesgo , Sarcoma/epidemiología , Sarcoma/genética , Sarcoma/terapia , Neoplasias Uterinas/epidemiología , Neoplasias Uterinas/genética , Neoplasias Uterinas/terapia
16.
Obstet Gynecol Clin North Am ; 23(2): 475-543, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784888

RESUMEN

Ovarian cancer accounts for only 4% of cancers in women, but it is the leading cause of death from gynecologic malignancies in the United States. In the general population, a woman's lifetime risk of ovarian cancer is 1.4% but this risk can increase substantially in women with a strong family history of the disease. The high mortality rate from ovarian cancer is due primarily to the difficulty in detecting the disease in early stages; the disease tends to be asymptomatic until it is well advanced. The primary care physician needs to be alert to the possibility of an ovarian malignancy in all women with an intact ovary or ovaries who present with abdominal or pelvic complaints. There are no current recommendations for routine screening for ovarian cancer in the general population. Even in high-risk women, there are currently no convincing data to support extensive screening, although a number of studies looking at this issue are under way. Despite this lack of conclusive evidence, a consensus panel on ovarian cancer convened by the NIH recently issued guidelines for screening high-risk women. They recommend annual rectovaginal pelvic examination, testing of CA 125 level, and transvaginal ultrasonography. Color flow Doppler analysis of the ovarian vessels is also being studied as a possible screening modality. BRCA1 gene testing may soon play a role in women with a strong family history of the disease. Given its high mortality rate, primary prevention strategies for ovarian cancer should be used whenever possible. Oral contraceptive use appears to reduce the risk of ovarian cancer. Prophylactic oophorectomy may be suggested for women at particularly high risk of the disease. Here, too, the primary care physician can play an important role in helping a patient understand the risks and benefits of these options.


Asunto(s)
Carcinoma in Situ/epidemiología , Carcinoma in Situ/patología , Neoplasias Ováricas/epidemiología , Neoplasias Ováricas/patología , Biomarcadores de Tumor , Carcinoma in Situ/genética , Carcinoma in Situ/mortalidad , Carcinoma in Situ/terapia , Femenino , Humanos , Tamizaje Masivo , Neoplasias Ováricas/genética , Neoplasias Ováricas/mortalidad , Neoplasias Ováricas/terapia , Factores de Riesgo
17.
Obstet Gynecol Clin North Am ; 23(2): 545-71, 1996 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-8784889

RESUMEN

GTD occurs in fewer than 1 in 1200 pregnancies in the United States, but it is much more common in Asia and Latin America, where its incidence may be as high as 1 in 200 pregnancies. Risk factors for GTD include advanced or young maternal age, low socioeconomic status, and prior hydatidiform mole. Early diagnosis and prompt treatment are key to a favorable outcome, and thus recognition of the signs and symptoms of the disease is important for all physicians. Because these diseases have low incidences and occur after reproductive events, screening for them in the general population is not worthwhile. No chemopreventive agents have yet been studied in women at risk for GTD, but the oral contraceptive is a good candidate.


Asunto(s)
Neoplasias Trofoblásticas/epidemiología , Neoplasias Trofoblásticas/patología , Neoplasias Uterinas/epidemiología , Neoplasias Uterinas/patología , Biomarcadores de Tumor , Femenino , Humanos , Tamizaje Masivo , Embarazo , Factores de Riesgo , Neoplasias Trofoblásticas/genética , Neoplasias Trofoblásticas/terapia , Neoplasias Uterinas/genética , Neoplasias Uterinas/terapia
18.
Mol Cell Endocrinol ; 118(1-2): 173-9, 1996 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-8735603

RESUMEN

Estrogen receptor variants lacking internal exons and representing dominant positive and negative activity may be involved in the initiation and/or progression of endocrine dependent tumors. To assess the role of estrogen receptor in uterine disease, we have analyzed both normal and neoplastic uterine samples for the presence of variant estrogen receptors using the sensitive technique of RT-PCR and direct automated DNA sequencing of the amplified products. Our analysis was conducted to determine the presence of spliced variants lacking exons 3 through exon 8. We demonstrate that both the normal and neoplastic human uterus contains a number of spliced variants of the estrogen receptor that co-exist with the wild type receptor. Variants lacking exons 4, 5 and 7 but not exons 3 and 6 were detected. Also, a novel partial deletion in exon 8 was detected in both the normal and neoplastic tissues, although a total deletion of this exon was not observed. In addition another region of exon 8 deletion was found to be present in one tumor tissue which also contained an insertion within this region, however, other tumors did not contain this variant. In addition, double exon deletion variants were observed lacking exons 3 and 4, exons 4 and 5, and exon 7 with part of exon 8. Although our data represents a limited number of samples it suggests that splicing of the estrogen receptor message occurs in the normal physiological setting. There does not appear to be any association between the presence or absence of spliced variants of estrogen receptor and uterine tumor formation at the mRNA level.


Asunto(s)
Adenocarcinoma/genética , Neoplasias Endometriales/genética , Endometrio/metabolismo , Neoplasias Ováricas/genética , Receptores de Estrógenos/genética , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Anciano , Anciano de 80 o más Años , Empalme Alternativo , Neoplasias Endometriales/metabolismo , Neoplasias Endometriales/patología , Endometrio/patología , Femenino , Eliminación de Gen , Expresión Génica , Humanos , Persona de Mediana Edad , Neoplasias Ováricas/metabolismo , Neoplasias Ováricas/patología , Receptores de Estrógenos/fisiología , Células Tumorales Cultivadas
19.
Biol Reprod ; 52(5): 1038-49, 1995 May.
Artículo en Inglés | MEDLINE | ID: mdl-7626703

RESUMEN

The endometrium is a dynamic tissue that, in response to hormonal cues, undergoes cycles of growth and involution. Extracellular factors required for this remodeling are poorly understood. The potential role in endometrial turnover of apolipoprotein J (apoJ), a secretory glycoprotein that can bind lipids and membrane-active proteins, is proposed on the basis of its spatial and temporal patterns of expression during normal cycling, after ovariectomy, and in response to hormone manipulation. In the mouse, apoJ mRNA was expressed in uterine luminal and glandular epithelial cells coincident with the presence of apoJ protein. The apoJ gene was differentially expressed in the glandular and uterine luminal epithelial cells during the estrous cycle and following hormone depletion. Expression of apoJ was not induced in ovariectomized mice by estrogen, progesterone, or dexamethasone treatment alone. Progesterone administration after an initial estrogen pretreatment, however, resulted in dramatic induction of apoJ as the progesterone level declined. In contrast, apoJ was not induced when a long-lived progesterone analog, medroxyprogesterone, was substituted for progesterone. In the human menstrual cycle, apoJ was present in glandular lumens only during the late secretory phase. Declining progesterone levels, causing substantial tissue reorganization, are characteristic of the times of marked apoJ induction in uterine epithelial cells. These expression patterns are consistent with apoJ functioning as an extracellular cytoprotectant by mediating clearance of and/or neutralizing cytolytic tissue debris.


Asunto(s)
Endometrio/metabolismo , Expresión Génica , Glicoproteínas/genética , Chaperonas Moleculares , Animales , Clusterina , Dexametasona/farmacología , Endometrio/efectos de los fármacos , Estradiol/farmacología , Femenino , Humanos , Inmunohistoquímica , Ciclo Menstrual/fisiología , Ratones , Ratones Endogámicos C57BL , Ovariectomía , Progesterona/farmacología , ARN Mensajero/metabolismo
20.
J Cell Biochem Suppl ; 23: 184-8, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-8747395

RESUMEN

Women at risk of uterine cancer include those with one or more of the following characteristics: obesity, nulliparity, late menopause, diabetes mellitus, prolonged unopposed estrogen use, and tamoxifen therapy. Risk is additionally increased by the presence of endometrial hyperplasia. The incorporation of biomarkers into the selection criteria of cohort groups at risk for developing endometrial cancer offers an innovative approach to the clinical design of chemoprevention trials of endometrial adenocarcinoma. Biomarkers that may be useful in cohort selection include nuclear morphometry, specific genetic abnormalities, and markers of proliferation and differentiation.


Asunto(s)
Adenocarcinoma/prevención & control , Anticarcinógenos/uso terapéutico , Biomarcadores de Tumor/análisis , Selección de Paciente , Neoplasias Uterinas/prevención & control , Adenocarcinoma/química , Ensayos Clínicos como Asunto , Femenino , Humanos , Factores de Riesgo , Neoplasias Uterinas/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...